McKesson Settles 2018 Price Fixing Suit With $141m Payment
Class Of Shareholders Had Alleged Financials ‘Premised On Illegal Activity’
Executive Summary
US distribution giant McKesson has reached a nine-figure settlement deal with shareholders to resolve a class action lawsuit alleging that it participated in a price-fixing and anticompetitive scheme for generic drugs with manufacturers and other wholesalers.
You may also be interested in...
Teva Agrees To $420m Securities Settlement For Alleged Price Fixing
Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.
McKesson shuffles pack
US-based wholesaler and retailer McKesson Corporation is to promote president and chief operating officer Brian Tyler to the role of chief executive officer following the retirement of John Hammergren.
US Supreme Court Reignites Claims Government Overcharged Millions For Generics
In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.